A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Participants
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT04023877
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States
A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy
- Conditions
- Pediatric Epileptic SyndromePartial-onset Seizures
- Interventions
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT04015141
- Locations
- 🇺🇸
PANDA, Atlanta, Georgia, United States
🇺🇸Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸David Geffen School of Medicine at UCLA, Los Angeles, California, United States
A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia
- Conditions
- Insomnia
- Interventions
- Drug: LEM 5 mgDrug: LEM 10 mg
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2021-04-12
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT04009577
- Locations
- 🇺🇸
Northern California Research Corp, Sacramento, California, United States
🇺🇸PACT, Glendale, Arizona, United States
🇺🇸Artemis Institute For Clinical Research LLC - San Diego - ClinEdge - PPDS, San Diego, California, United States
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
- Conditions
- NeoplasmsLiver NeoplasmsColorectal NeoplasmsEndometrial NeoplasmsCarcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 301
- Registration Number
- NCT04008797
- Locations
- 🇫🇷
ICANs, Strasbourg, France
🇫🇷Gustave Roussy Institute (IGR), Villejuif, France
🇮🇹Clinica Oncologica AOU (Azienda Ospedaliero Universitaria) delle Marche, Ancona, Italy
A Food-Effect Study of E7386 in Healthy Participants
- First Posted Date
- 2019-06-24
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT03996226
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
- Conditions
- Early Alzheimer's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 1906
- Registration Number
- NCT03887455
- Locations
- 🇺🇸
Emory University Cognitive Neurology Clinic & ADRC, Atlanta, Georgia, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303
- Conditions
- Lennox Gastaut Syndrome
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Eisai Inc.
- Registration Number
- NCT03778424
- Locations
- 🇵🇱
Generała Tadeusza Kościuszki 52, Kielce, Poland
🇵🇱Szpital Kliniczny im. Heliodora Święcickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznań, Poland
A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2020-09-28
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03686033
- Locations
- 🇺🇸
Consultants in Epilepsy & Neurology, PLLC, Boise, Idaho, United States
🇺🇸Washington University Hospital, Saint Louis, Missouri, United States
🇺🇸Clinical Trials, Inc. and Arkansas Epilepsy Program, Little Rock, Arkansas, United States
A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 713
- Registration Number
- NCT03663114
- Locations
- 🇯🇵
Eisai trial site 1, Osaka, Japan
🇯🇵Eisai trial site 2, Tokyo, Japan
A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03627936
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States